S-1/A: Revelation Biosciences Announces Offering of Common Stock and Warrants

Revelation Biosciences plans a best efforts public offering of common stock, pre-funded warrants, and Class D Common Stock Warrants to raise capital for clinical development and general corporate purposes.

Summary

• Revelation Biosciences is undertaking a best efforts public offering.
• The offering includes shares of common stock, pre-funded warrants, and Class D Common Stock Warrants.
• The goal is to raise capital for the development of GEM-SSI, GEM-AKI, and GEM-CKD, as well as for general corporate purposes.
• The offering involves 793,651 shares of common stock, warrants to purchase up to 1,587,302 shares of common stock (Class D Common Stock Warrants), and shares underlying those warrants.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limitations.
• The assumed public offering price is $12.60 per share and accompanying two Class D Common Stock Warrants.
• The company intends to use the net proceeds to further the development of GEM -SSI , GEM -AKI and GEM -CKD including the (i) to conduct, a combined Phase 1a clinical study for GEM -SSI and GEM -AKI , (ii) to conduct, a Phase 1b clinical study for GEM -SSI for the prevention of surgical site infection in colorectal surgery, (iii) to conduct, a Phase 1b clinical study for GEM -AKI for the prevention and treatment of AKI due to cardiac surgery, (iv) necessary preclinical work for GEM -CKD , (v) continue to develop other products and therapies, and (vi) fund working capital and general corporate purposes using any remaining amounts.
• Roth Capital Partners, LLC is acting as the exclusive placement agent.
• The offering will terminate on the earlier of (i) the first date that we enter into securities purchase agreements to sell the securities offered hereby, or (ii) 25 days after the effective date of the registration statement of which this prospectus forms a part.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The announcement is a standard capital raise, which is neither inherently positive nor negative. The success of the offering and the subsequent use of funds will determine the long-term impact.

Positives

• Capital raised will support the advancement of Revelation Biosciences' clinical programs (GEM-SSI, GEM-AKI, GEM-CKD).

Negatives

• The offering is on a 'best efforts' basis, meaning there's no guarantee of raising the full amount.
• The company will incur immediate and substantial dilution in the net tangible book value of the shares.

Risks

• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• There is no public market for the warrants or pre-funded warrants being offered.
• The warrants and pre-funded warrants are speculative in nature.
• Holders of the warrants offered hereby will have no rights as common stockholders with respect to the shares our common stock underlying the warrants until such holders exercise their warrants and acquire our common stock, except as otherwise provided in the warrants.
• This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near -term business plans.

Future Outlook

The company expects to use the net proceeds from this offering to further the development of GEM -SSI , GEM -AKI and GEM -CKD including the (i) to conduct, a combined Phase 1a clinical study for GEM -SSI and GEM -AKI , (ii) to conduct, a Phase 1b clinical study for GEM -SSI for the prevention of surgical site infection in colorectal surgery, (iii) to conduct, a Phase 1b clinical study for GEM -AKI for the prevention and treatment of AKI due to cardiac surgery, (iv) necessary preclinical work for GEM -CKD , (v) continue to develop other products and therapies, and (vi) fund working capital and general corporate purposes using any remaining amounts.

Industry Context

The announcement reflects the ongoing capital-raising activities within the biopharmaceutical industry, particularly for companies in the clinical development stage. The funds are earmarked for advancing drug candidates, a common theme among similar companies.

Stakeholder Impact

• Shareholders will experience dilution.
• Employees may benefit from increased funding for research and development.
• The company may be able to advance its clinical programs and potentially bring new therapies to market.

Next Steps

• The company will enter into securities purchase agreements to sell the securities offered.
• The company will deliver the securities being issued to the investors upon receipt of investor funds.
• The company will use the net proceeds from this offering to further the development of GEM -SSI , GEM -AKI and GEM -CKD including the (i) to conduct, a combined Phase 1a clinical study for GEM -SSI and GEM -AKI , (ii) to conduct, a Phase 1b clinical study for GEM -SSI for the prevention of surgical site infection in colorectal surgery, (iii) to conduct, a Phase 1b clinical study for GEM -AKI for the prevention and treatment of AKI due to cardiac surgery, (iv) necessary preclinical work for GEM -CKD , (v) continue to develop other products and therapies, and (vi) fund working capital and general corporate purposes using any remaining amounts.

Key Dates

Keywords

public offering, common stock, warrants, Revelation Biosciences, capital raise, biopharmaceutical, GEM-SSI, GEM-AKI, GEM-CKD, Roth Capital Partners